Optimal Treatment of Acute Skeletal Muscle Injury

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBispebjerg Hospital

About this trial

Acute muscle strain injuries occur both during sports, in leisure time activities and during manual occupation and represent a major clinical challenge and has societal economic costs. The recovery time is long and a substantial injury recurrence is observed. Despite current best evidence rehabilitation with early mechanical loading, a significant loss of muscle mass, fatty infiltration and formation of scar tissue is reported.

Animal models and human in vitro experiments suggest that inflammation is vital in the early period after an injury, however an inhibition of inflammatory processes is beneficial for healing.

We investigate here whether a pharmacological inhibition of inflammatory pathways in the 2nd week following a muscle strain injury will provide a better clinical outcome and an advantageous cellular profile than rehabilitative training alone would.

Eligibility criteria

Qualifiers

Sports-active individuals with an acute muscle train injury in either the hamstrings or calf muscle caused by an explosive movement (during sprinting, jumping etc)

Age older than 18 years

Disqualifiers

Lack of hypoechoic/ hyperechoic area on ultrasound

Diabetes type I and II

Connective tissue disorders, rheumatism or any other chronic disease affecting the musculoskeletal system

Anticoagulant medication

Trial design

Treatments tested in this trial

  • Naproxen 500 Mg
  • Rehabilitation
  • Placebo

Treatment groups

20 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators